QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF For Our Patients Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hester, E K. Articles by Sims, K. M Search for Related Content PubMed PubMed Citation Articles by Hester, E K. Articles by Sims, K. M

FORMULARY FORUM

Fosamprenavir: Drug Development for Adherence

Assistant Clinical Professor, Department of Pharmacy Practice, Harrison School of Pharmacy, Auburn University, AL

Haley V Chandler, PharmD Student

Harrison School of Pharmacy

Kelli M Sims, PharmD Student

Harrison School of Pharmacy

Reprints: Dr. Hester, Harrison School of Pharmacy, 125 Walker Building, Auburn University, AL 36849-5502, fax 334/844-4019, hesteek{at}auburn.edu

OBJECTIVE: To review the pharmacology, pharmacokinetics, virology, safety, efficacy, and clinical use of fosamprenavir.

DATA SOURCES: A MEDLINE (1966-July 2005) search was conducted using fosamprenavir, Lexiva, amprenavir, and GW433908 as key words. Abstracts from infectious diseases and HIV scientific meetings were identified. Bibliographies of cited articles were reviewed.

STUDY SELECTION AND DATA EXTRACTION: All publications, meeting abstracts, and unpublished information were reviewed and relevant items included. Information from in vitro, preclinical, and Phase II and III clinical trials was included.

DATA SYNTHESIS: Fosamprenavir is a protease inhibitor (PI) prodrug used for the treatment of HIV-1 infection. The active moiety, amprenavir, is extensively metabolized by CYP3A4. In clinical trials, fosamprenavir was at least as effective as amprenavir, with a reduced pill burden. Fosamprenavir was developed with the intention of reducing the pill burden associated with amprenavir. It has demonstrated comparable safety and efficacy with comparator PIs and is associated with limited cross-resistance to other PIs.

CONCLUSIONS: Fosamprenavir is a promising antiretroviral agent with favorable efficacy and tolerability. At this time, data indicate the utility of fosamprenavir in treatment-naïve and PI-experienced HIV-infected patients.

Key Words: fosamprenavir, GW433908, Lexiva

Published Online, June 6, 2006. www.theannals.com, DOI 10.1345/aph.1G034

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-06-015-H02

This article has been cited by other articles:

				J. Borras-Blasco, A. Navarro-Ruiz, C. Borras, and E. Castera Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection J. Antimicrob. Chemother., November 1, 2008; 62(5): 879 - 888. [Abstract] [Full Text] [PDF]

				L Calza, R Manfredi, D Pocaterra, and F Chiodo Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-nayive patients with HIV-1 infection Int J STD AIDS, August 1, 2008; 19(8): 541 - 544. [Abstract] [Full Text] [PDF]